{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:49:33Z","timestamp":1778132973404,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC 260\/01 2022"],"award-info":[{"award-number":["RC 260\/01 2022"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several risk factors for Coronavirus-2019 (COVID-19) disease have been highlighted in clinical evidence. Among the various risk factors are advanced age, metabolic illness such as diabetes, heart disease, and diseases of the respiratory system. Cystic Fibrosis (CF) is a rare disease with autosomal recessive transmission, characterised by a lack of synthesis of the CFTR channel protein, and multi-organ clinical symptoms mainly affecting the respiratory tract with recurrent pulmonary exacerbations. In view of the pathophysiological mechanisms, CF disease should be in theory considered a risk factor for SARS-CoV2 or severe COVID-19. However, recent clinical evidence seems to point in the opposite direction, suggesting that CF could be a protective factor against severe COVID-19. Possibly, the lack of presence or function of the CFTR channel protein could be linked to the expression of the membrane glycoprotein ACE-2, a key enzyme for the endocellular penetration of SARS-CoV-2 and related to the pathophysiology of COVID-19 disease. Furthermore, CFTR channel modulating agents could indirectly influence the expression of ACE-2, playing an important role in restoring the proper functioning of mucociliary clearance and the pulmonary microbiome in the host response to SARS-CoV-2 infection. In this review, the authors attempt to shed light on these important associations of issues that are not yet fully elucidated.<\/jats:p>","DOI":"10.1186\/s12931-023-02593-1","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:02:10Z","timestamp":1699891330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review"],"prefix":"10.1186","volume":"24","author":[{"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-1780","authenticated-orcid":false,"given":"Michela","family":"Sabbatucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Silenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"issue":"12","key":"2593_CR1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/life12122087","volume":"12","author":"C Biondo","year":"2022","unstructured":"Biondo C, Midiri A, Gerace E, Zummo S, Mancuso G. SARS-CoV-2 infection in patients with cystic fibrosis: what we know so far. Life (Basel). 2022;12(12):2087. https:\/\/doi.org\/10.3390\/life12122087.","journal-title":"Life (Basel)"},{"issue":"1","key":"2593_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03136-22","volume":"14","author":"JM Honrubia","year":"2023","unstructured":"Honrubia JM, Gutierrez-\u00c1lvarez J, Sanz-Bravo A, et al. SARS-CoV-2-mediated lung edema and replication are diminished by cystic fibrosis transmembrane conductance regulator modulators. MBio. 2023;14(1): e0313622. https:\/\/doi.org\/10.1128\/mbio.03136-22.","journal-title":"MBio"},{"issue":"8","key":"2593_CR3","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/cells11081347","volume":"11","author":"V Lotti","year":"2022","unstructured":"Lotti V, Merigo F, Lagniet A, et al. CFTR modulation reduces SARS-CoV-2 infection in human bronchial epithelial cells. Cells. 2022;11(8):1347. https:\/\/doi.org\/10.3390\/cells11081347.","journal-title":"Cells"},{"issue":"5","key":"2593_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/cells12050776","volume":"12","author":"A Lagni","year":"2023","unstructured":"Lagni A, Lotti V, Diani E, et al. CFTR inhibitors display in vitro antiviral activity against SARS-CoV-2. Cells. 2023;12(5):776. https:\/\/doi.org\/10.3390\/cells12050776.","journal-title":"Cells"},{"issue":"3","key":"2593_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ije\/dyaa033","volume":"49","author":"NC Peeri","year":"2020","unstructured":"Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49(3):717\u201326. https:\/\/doi.org\/10.1093\/ije\/dyaa033.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2593_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12931-020-01479-w","volume":"21","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21(1):224. https:\/\/doi.org\/10.1186\/s12931-020-01479-w.","journal-title":"Respir Res"},{"issue":"1","key":"2593_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/biomedicines10010188","volume":"10","author":"D Petrovszki","year":"2022","unstructured":"Petrovszki D, Walter FR, Vigh JP, et al. Penetration of the SARS-CoV-2 spike protein across the blood-brain barrier, as revealed by a combination of a human cell culture model system and optical biosensing. Biomedicines. 2022;10(1):188. https:\/\/doi.org\/10.3390\/biomedicines10010188.","journal-title":"Biomedicines"},{"issue":"12","key":"2593_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.630778","volume":"9","author":"E Balse","year":"2021","unstructured":"Balse E, Hatem SN. Do Cellular entry mechanisms of SARS-Cov-2 affect myocardial cells and contribute to cardiac injury in COVID-19 patients? Front Physiol. 2021;9(12): 630778. https:\/\/doi.org\/10.3389\/fphys.2021.630778.","journal-title":"Front Physiol"},{"issue":"5","key":"2593_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1080\/13685538.2020.1774748","volume":"23","author":"M Parohan","year":"2020","unstructured":"Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416\u201324. https:\/\/doi.org\/10.1080\/13685538.2020.1774748.","journal-title":"Aging Male"},{"issue":"1","key":"2593_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","volume":"21","author":"ZG Dessie","year":"2021","unstructured":"Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855. https:\/\/doi.org\/10.1186\/s12879-021-06536-3.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"2593_CR11","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1128\/JCM.01604-13","volume":"51","author":"WG Flight","year":"2013","unstructured":"Flight WG, Bright-Thomas RJ, Tilston P, et al. Chronic rhinovirus infection in an adult with cystic fibrosis. J Clin Microbiol. 2013;51(11):3893\u20136. https:\/\/doi.org\/10.1128\/JCM.01604-13.","journal-title":"J Clin Microbiol"},{"issue":"930","key":"2593_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/pmj.79.930.201","volume":"79","author":"D Wat","year":"2003","unstructured":"Wat D. Impact of respiratory viral infections on cystic fibrosis. Postgrad Med J. 2003;79(930):201\u20133. https:\/\/doi.org\/10.1136\/pmj.79.930.201.","journal-title":"Postgrad Med J"},{"issue":"3","key":"2593_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1556\/EuJMI.2.2012.3.1","volume":"2","author":"H Frickmann","year":"2012","unstructured":"Frickmann H, Jungblut S, Hirche TO, Gro\u00df U, Kuhns M, Zautner AE. Spectrum of viral infections in patients with cystic fibrosis. Eur J Microbiol Immunol. 2012;2(3):161\u201375. https:\/\/doi.org\/10.1556\/EuJMI.2.2012.3.1.","journal-title":"Eur J Microbiol Immunol."},{"key":"2593_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251527","volume":"16","author":"C Colombo","year":"2021","unstructured":"Colombo C, et al. SARS-CoV-2 infection in cystic fibrosis: a multicentre prospective study with a control group, Italy, February-July 2020. PLoS ONE. 2021;16: e0251527.","journal-title":"PLoS ONE"},{"key":"2593_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jcf.2021.03.017","volume":"20","author":"L Naehrlich","year":"2021","unstructured":"Naehrlich L, et al. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between february and june 2020. J Cyst Fibros. 2021;20:566\u201377.","journal-title":"J Cyst Fibros"},{"key":"2593_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106062","volume":"170","author":"P Mondejar-Lopez","year":"2020","unstructured":"Mondejar-Lopez P, et al. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: incidence and results of the national CF-COVID19-spain survey. Respir Med. 2020;170: 106062.","journal-title":"Respir Med"},{"key":"2593_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jcf.2021.01.008","volume":"20","author":"R Padoan","year":"2021","unstructured":"Padoan R, et al. First and second wave of SARS-CoV2 in Italian cystic fibrosis patients: data from Italian cystic fibrosis registry. J Cyst Fibros. 2021;20:372\u20133.","journal-title":"J Cyst Fibros"},{"issue":"11","key":"2593_CR18","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.3390\/jcm9113624","volume":"9","author":"H Corvol","year":"2020","unstructured":"Corvol H, et al. First wave of COVID-19 in French patients with cystic fibrosis. J Clin Med. 2020;9(11):3624.","journal-title":"J Clin Med"},{"key":"2593_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jcf.2020.08.005","volume":"19","author":"S Berardis","year":"2020","unstructured":"Berardis S, et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. J Cyst Fibros. 2020;19:872\u20134.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"2593_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.958658","volume":"8","author":"V Terlizzi","year":"2022","unstructured":"Terlizzi V, Motisi MA, Pellegrino R, Padoan R, Chiappini E. Risk factors for severe COVID-19 in people with cystic fibrosis: a systematic review. Front Pediatr. 2022;8(10): 958658. https:\/\/doi.org\/10.3389\/fped.2022.958658.","journal-title":"Front Pediatr"},{"key":"2593_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26427","author":"L Noij","year":"2023","unstructured":"Noij L, Haarman E, Hashimoto S, et al. Depression, anxiety, and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers. Ped Pulm. 2023. https:\/\/doi.org\/10.1002\/ppul.26427.","journal-title":"Ped Pulm"},{"issue":"10","key":"2593_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.978627","volume":"14","author":"N Oubaya","year":"2022","unstructured":"Oubaya N, Pombet T, Delestrain C, et al. Impact of the COVID-19 pandemic and associated lockdown measures on the management, health, and behavior of the cystic fibrosis population in France during 2020 (MUCONFIN). Front Public Health. 2022;14(10): 978627. https:\/\/doi.org\/10.3389\/fpubh.2022.978627.","journal-title":"Front Public Health"},{"key":"2593_CR23","doi-asserted-by":"publisher","first-page":"16056","DOI":"10.3390\/ijerph192316056","volume":"19","author":"M Humaj-Grysztar","year":"2022","unstructured":"Humaj-Grysztar M, Rachel M, Smiech-Michalec O, Bonior J. Mental Health of cystic fibrosis patients and the COVID-19 pandemic in Poland: a single-center comparative study. Int J Environ Res Public Health. 2022;19:16056.","journal-title":"Int J Environ Res Public Health"},{"key":"2593_CR24","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/biomedicines10112771","volume":"10","author":"P Medino","year":"2022","unstructured":"Medino P, Alicandro G, Rosazza C, et al. Impact of COVID-19 on lung disease in people with cystic fibrosis: a 6-month follow-up study on respirator outcomes. Biomedicines. 2022;10:2771.","journal-title":"Biomedicines"},{"key":"2593_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.09.006","author":"M Doumit","year":"2022","unstructured":"Doumit M, Chuang S, Middleton P, et al. Clinical outcomes of adults and children with cystic fibrosis during COVID-19 pandemic. J Cyst Fibros. 2022. https:\/\/doi.org\/10.1016\/j.jcf.2022.09.006.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2593_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12890-021-01528-0","volume":"21","author":"HR Mathew","year":"2021","unstructured":"Mathew HR, Choi MY, Parkins MD, Fritzler MJ. Systematic review: cystic fibrosis in the SARS-CoV-2\/COVID-19 pandemic. BMC Pulm Med. 2021;21(1):173. https:\/\/doi.org\/10.1186\/s12890-021-01528-0.","journal-title":"BMC Pulm Med"},{"key":"2593_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106606","volume":"188","author":"YB Hadi","year":"2021","unstructured":"Hadi YB, Lakhani DA, Naqvi SF, Naqvi SF, Fatima NU, Sarwari AR, et al. Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: a multicenter retrospective research network study. Respir Med. 2021;188: 106606. https:\/\/doi.org\/10.1016\/j.rmed.2021.106606.","journal-title":"Respir Med"},{"issue":"4","key":"2593_CR28","doi-asserted-by":"publisher","first-page":"00411","DOI":"10.1183\/23120541.00411-2021","volume":"7","author":"A Jung","year":"2021","unstructured":"Jung A, Orenti A, Dunlevy F, Aleksejeva E, Bakkeheim E, Bobrovnichy V, et al. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Res. 2021;7(4):00411\u20132021. https:\/\/doi.org\/10.1183\/23120541.00411-2021.","journal-title":"ERJ Open Res"},{"issue":"6","key":"2593_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jcf.2020.10.003","volume":"19","author":"E McClenaghan","year":"2020","unstructured":"McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes CA, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros. 2020;19(6):868\u201371. https:\/\/doi.org\/10.1016\/j.jcf.2020.10.003.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2593_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"issue":"2","key":"2593_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, et al. Function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.e6. https:\/\/doi.org\/10.1016\/j.cell.2020.02.058. (Erratum in: Cell. 2020 Dec 10;183(6):1735).","journal-title":"Cell"},{"issue":"4","key":"2593_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1871528113666140713164506","volume":"13","author":"RR Gaddam","year":"2014","unstructured":"Gaddam RR, Chambers S, Bhatia M. ACE and ACE2 in inflammation: a tale of two enzymes. Inflamm Allergy Drug Targets. 2014;13(4):224\u201334. https:\/\/doi.org\/10.2174\/1871528113666140713164506.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"6","key":"2593_CR33","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/j.1476-5381.2012.01905.x","volume":"166","author":"AZ El-Hashim","year":"2012","unstructured":"El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin-(1\u20137) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1\/2- and NF-kappaB-dependent pathways. Br J Pharmacol. 2012;166(6):1964\u201376. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01905.x.","journal-title":"Br J Pharmacol"},{"key":"2593_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2021.09.007","volume":"93","author":"F Angeli","year":"2021","unstructured":"Angeli F, Zappa M, Reboldi G, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: one year later. Eur J Intern Med. 2021;93:28\u201334. https:\/\/doi.org\/10.1016\/j.ejim.2021.09.007.","journal-title":"Eur J Intern Med"},{"issue":"22","key":"2593_CR35","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.3390\/molecules26226945","volume":"26","author":"G El-Arif","year":"2021","unstructured":"El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: a key role in SARS-CoV-2-induced COVID-19. Molecules. 2021;26(22):6945. https:\/\/doi.org\/10.3390\/molecules26226945.","journal-title":"Molecules"},{"issue":"4","key":"2593_CR36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.drudis.2021.01.010","volume":"26","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021;26(4):870\u20134. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.010.","journal-title":"Drug Discov Today"},{"issue":"6","key":"2593_CR37","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jcf.2020.08.005","volume":"19","author":"S Berardis","year":"2020","unstructured":"Berardis S, Verroken A, Vetillart A, et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. J Cyst Fibros. 2020;19(6):872\u20134. https:\/\/doi.org\/10.1016\/j.jcf.2020.08.005.","journal-title":"J Cyst Fibros"},{"key":"2593_CR38","doi-asserted-by":"publisher","first-page":"L408","DOI":"10.1152\/ajplung.00225.2020","volume":"319","author":"BA Stanton","year":"2020","unstructured":"Stanton BA, Hampton TH, Ashare A. SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2020;319:L408\u201315. https:\/\/doi.org\/10.1152\/ajplung.00225.2020.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2593_CR39","unstructured":"Cystic fibrosis foundation. https:\/\/www.cff.org\/managing-cf\/cftr-modulator-therapies.\u00a0Accessed 30 Sept 2023."},{"issue":"74","key":"2593_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","volume":"27","author":"S Jia","year":"2023","unstructured":"Jia S, Taylor-Cousar JL. Cystic fibrosis modulator therapies. Annu Rev Med. 2023;27(74):413\u201326. https:\/\/doi.org\/10.1146\/annurev-med-042921-021447.","journal-title":"Annu Rev Med"},{"issue":"3","key":"2593_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit G, Avramescu RG, Chiang AN, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016;27(3):424\u201333. https:\/\/doi.org\/10.1091\/mbc.E14-04-0935.","journal-title":"Mol Biol Cell"},{"issue":"10","key":"2593_CR42","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"21","author":"M Lopes-Pacheco","year":"2020","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2020;21(10):1662. https:\/\/doi.org\/10.3389\/fphar.2019.01662.","journal-title":"Front Pharmacol"},{"key":"2593_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","volume":"10","author":"RVE Dagenais","year":"2021","unstructured":"Dagenais RVE, Su VC, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review. J Clin Med. 2021;10:23. https:\/\/doi.org\/10.3390\/jcm10010023.","journal-title":"J Clin Med"},{"issue":"12","key":"2593_CR44","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1002\/ppul.25627","volume":"56","author":"DM Goetz","year":"2021","unstructured":"Goetz DM, Savant AP. Review of CFTR modulators 2020. Pediatr Pulmonol. 2021;56(12):3595\u2013606. https:\/\/doi.org\/10.1002\/ppul.25627.","journal-title":"Pediatr Pulmonol"},{"issue":"18","key":"2593_CR45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663\u201372. https:\/\/doi.org\/10.1056\/NEJMoa1105185.","journal-title":"N Engl J Med"},{"issue":"4","key":"2593_CR46","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","volume":"128","author":"AL Quittner","year":"2005","unstructured":"Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128(4):2347\u201354. https:\/\/doi.org\/10.1378\/chest.128.4.2347.","journal-title":"Chest"},{"key":"2593_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220\u201331.","journal-title":"N Engl J Med"},{"key":"2593_CR48","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809\u201319.","journal-title":"N Engl J Med"},{"key":"2593_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jcf.2015.01.008","volume":"15","author":"J Taylor-Cousar","year":"2016","unstructured":"Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2016;15:116\u201322.","journal-title":"J Cyst Fibros"},{"key":"2593_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","volume":"201","author":"VA Stalling","year":"2018","unstructured":"Stalling VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations. J Pediatr. 2018;201:229\u201337.","journal-title":"J Pediatr"},{"key":"2593_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jcf.2013.05.006","volume":"12","author":"H Hebestreit","year":"2013","unstructured":"Hebestreit H, Sauer-Heilborn A, Fischer R, Kading M, Mainz JG. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. J Cyst Fibros. 2013;12:599\u2013603.","journal-title":"J Cyst Fibros"},{"key":"2593_CR52","doi-asserted-by":"crossref","unstructured":"Al-Rashdi Z, Al-Busaidi N. The effect of ivacaftor on adult cystic fibrosis patients at the Royal Hospital in Oman. In: Proceedings of the 42nd European Cystic Fibrosis Conference. Liverpool, 5\u20138 June. 2019. p. 256.","DOI":"10.1016\/S1569-1993(19)30549-1"},{"key":"2593_CR53","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.arbres.2018.05.004","volume":"54","author":"L Diab-C\u00e1ceres","year":"2018","unstructured":"Diab-C\u00e1ceres L, Gir\u00f3n-Moreno RM, Pastor-Sanz MT, et al. Compassionate use of lumacaftor\/ivacaftor in cystic fibrosis: Spanish experience. Arch Bronconeumol. 2018;54:614\u20138.","journal-title":"Arch Bronconeumol"},{"key":"2593_CR54","doi-asserted-by":"crossref","unstructured":"Wareham JM, Webb KA, Jones AM et al. Lumacaftor\/ivacaftor is associated with high discontinuation rates in patients with baseline severe lung function but also benefits in those who tolerate therapy. In: Proceedings of the British Thoracic Society Winter Meeting, London, UK, 6\u20138 December 2017. p. 247.","DOI":"10.1136\/thoraxjnl-2017-210983.389"},{"key":"2593_CR55","doi-asserted-by":"crossref","unstructured":"Etherington C, Graham T, Spoletini G et al . Early experience of the Orkambi \u201cmanaged Access Programme\u201d in a regional adult UK CF centre. In: Proceedings of the 40th European cystic fibrosis conference, Seville, Spain, 7\u201310 June 2017. p. 56","DOI":"10.1016\/S1569-1993(17)30421-6"},{"key":"2593_CR56","unstructured":"Wadsworth L, Riley D, Johnson S, Barry P. Physiotherapeutic objective and subjective evaluation of lumacaftor\/ivacaftor initiation in patients with severe lung disease in a large adult CF centre. In: Proceedings of the 33rd Annual North American Cystic Fibrosis Conference, Nashville, TN, USA, 31 October\u20132 November 2019. p. 468. 18."},{"key":"2593_CR57","unstructured":"Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf.\u00a0\u00a0Accessed 30 Sept 2023."},{"issue":"1","key":"2593_CR58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","volume":"6","author":"L Yang","year":"2021","unstructured":"Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):255. https:\/\/doi.org\/10.1038\/s41392-021-00679-0. (Erratum.In:SignalTransductTargetTher.2021Aug31;6(1):326).","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2593_CR59","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","volume":"195","author":"KB Hisert","year":"2017","unstructured":"Hisert KB, Heltshe SL, Pope C, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit CareMed. 2017;195(12):1617\u201328.","journal-title":"Am J Respir Crit CareMed"},{"issue":"2","key":"2593_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jcf.2016.12.004","volume":"16","author":"TA Altes","year":"2017","unstructured":"Altes TA, Johnson M, Fidler M, et al. Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis. J Cyst Fibros. 2017;16(2):267\u201374.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"2593_CR61","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","volume":"195","author":"KB Hisert","year":"2017","unstructured":"Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit CareMed. 2017;195(12):1617\u201328. https:\/\/doi.org\/10.1164\/rccm.201609-1954OC.","journal-title":"Am J Respir Crit CareMed"},{"issue":"2","key":"2593_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jcf.2016.12.004","volume":"16","author":"TA Altes","year":"2017","unstructured":"Altes TA, Johnson M, Fidler M, Botfield M, Tustison NJ, Leiva-Salinas C, et al. Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis. J Cyst Fibros. 2017;16(2):267\u201374. https:\/\/doi.org\/10.1016\/j.jcf.2016.12.004.","journal-title":"J Cyst Fibros"},{"key":"2593_CR63","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/cells11081347","volume":"11","author":"V Lotti","year":"2022","unstructured":"Lotti V, Merigo F, Lagni A, Di Clemente A, Ligozzi M, Bernardi P, et al. CFTR modulation reduces SARS-CoV-2 infection in human bronchial epithelial cells. Cells. 2022;11:1347. https:\/\/doi.org\/10.3390\/cells11081347.","journal-title":"Cells"},{"issue":"1","key":"2593_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41467-023-35862-0","volume":"14","author":"V Bezzerri","year":"2023","unstructured":"Bezzerri V, Gentili V, Api M, et al. SARS-CoV-2 viral entry and replication is impaired in cystic fibrosis airways due to ACE2 downregulation. Nat Commun. 2023;14(1):132. https:\/\/doi.org\/10.1038\/s41467-023-35862-0.","journal-title":"Nat Commun"},{"issue":"1","key":"2593_CR65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-022-01048-1","volume":"7","author":"L Chen","year":"2022","unstructured":"Chen L, Guan W, Qiu Z, et al. SARS-CoV-2 nucleocapsid protein triggers hyperinflammation via protein\u2013protein interaction-mediated intracellular Cl- accumulation in respiratory epithelium. Signal Transduct Target Ther. 2022;7(1):255. https:\/\/doi.org\/10.1038\/s41392-022-01048-1.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02593-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02593-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02593-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:05:40Z","timestamp":1699891540000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02593-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2593"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02593-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Dr. Zovi reports grants from Chiesi, outside the submitted work; Dr. Blasi reports grants and personal fees from Astrazeneca, personal fees from Chiesi, grants and personal fees from Glaxosmithkline, personal fees from Grifols, grants and personal fees from Insmed, personal fees from Menarini, personal fees from Novartis, personal fees from Pfizer, personal fees from Sanofi, personal fees from OM Pharma, personal fees from Vertex, personal fees from Viatris, personal fees from Zambon, outside the submitted work. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}